文献速递瘢痕与激光创面修复

A型肉毒毒素改善瘢痕质量与创面愈合:随机对照试验的系统评价与荟萃分析

Efficacy of Botulinum Toxin Type A in Improving Scar Quality and Wound Healing: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
PubMed 文献 · Aesthet Surg J · 2020-01-01

该系统评价与荟萃分析纳入11项随机对照试验共486例(374例患者),比较A型肉毒毒素(BTA)与空白或安慰剂对照对外科瘢痕和创面的疗效。结果显示BTA组视觉模拟量表评分更高、温哥华瘢痕量表评分更低、瘢痕更窄且患者满意度更高,仅报告轻微不良事件。结论认为BTA在面颈部改善瘢痕质量和创面愈合优于对照,但证据不足以支持用于白人原发手术瘢痕或面颈部以外部位。

要点

  • BTA组温哥华瘢痕量表评分较对照降低1.62分(95%CI -2.49至-0.75,P=0.0003)。
  • BTA组瘢痕宽度较对照减少0.15(95%CI -0.20至-0.11,P<0.00001)。
  • BTA组患者满意度风险比为1.25(95%CI 1.06至1.49,P=0.01),仅轻微不良事件。

核心结论

  • BTA注射在面颈部改善瘢痕质量和创面愈合方面优于安慰剂或空白对照,且仅报告轻微不良事件。
  • 证据不足以支持BTA用于白人原发手术瘢痕或面颈部以外部位的瘢痕。

研究设计与样本

  • 系统评价与荟萃分析,检索Pubmed、Embase和Cochrane Library数据库的随机对照试验。
  • 纳入11项RCT,共486例(374例患者),比较BTA与空白或安慰剂对照对外科瘢痕和创面的疗效。

主要发现

  • BTA组视觉模拟量表评分显著高于对照组(MD=1.30,95%CI 1.05至1.55)。
  • BTA组温哥华瘢痕量表评分显著低于对照组(MD=-1.62,95%CI -2.49至-0.75,P=0.0003)。
  • BTA组瘢痕宽度显著薄于对照组(MD=-0.15,95%CI -0.20至-0.11,P<0.00001)。
  • BTA组患者满意度高于对照组(RR=1.25,95%CI 1.06至1.49,P=0.01)。
  • 仅报告轻微不良事件。

关键数值与推荐

  • 采用视觉模拟量表、温哥华瘢痕量表、瘢痕宽度和患者满意度评估结局,并记录不良事件。
  • BTA在面颈部改善瘢痕质量和创面愈合的证据支持用于亚洲人,但不支持用于白人原发手术瘢痕或面颈部以外部位。
  • 需进一步研究BTA的标准化注射方案和技术以指导临床实践。

临床怎么用

  • 对于亚洲患者面颈部瘢痕,可考虑BTA注射以改善瘢痕质量和患者满意度。
  • 白人原发手术瘢痕或面颈部以外部位的瘢痕,目前证据不足以推荐BTA治疗。
  • 临床应用中需注意BTA注射方案和技术尚未标准化,应关注后续研究。

局限性

  • 证据主要支持亚洲人面颈部瘢痕,对其他人群和部位证据不足。
  • BTA的标准化注射方案和技术尚未确定,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Botulinum toxin type A-induced "chemoimmobilization" has long been utilized for improved scar quality and wound healing; however, current evidence is limited to small studies, and evidence-based information is inadequate to make well-informed decisions. OBJECTIVES: The purpose of this study was to evaluate the efficacy of botulinum toxin type A (BTA) to improve scars and wound healing. METHODS: The authors searched databases, including Pubmed, Embase, and Cochrane Library, to identify randomized clinical trials (RCTs) that compared outcomes of surgical scars and wounds treated with BTA vs those treated with blank or placebo controls. The Visual Analog Scale, Vancouver Scar Score, scar width, and reported patient satisfaction were utilized in evaluating outcomes. Adverse events were also recorded. RESULTS: Eleven RCTs involved a total of 486 cases (374 patients). Quantitative synthesis suggested that compared with the control group, patients in the BTA treatment group had significantly higher Visual Analog Scale scores (mean difference [MD] = 1.30, 95% confidence interval [CI]: 1.05 to 1.55), lower Vancouver Scar Scores (MD = -1.62, 95% CI: -2.49 to -0.75, P = 0.0003), and thinner scars (MD = -0.15, 95% CI: -0.20 to -0.11, P < 0.00001). Patient satisfaction was higher in the BTA group than in the control group (risk ratio: 1.25, 95% CI: 1.06 to 1.49, P = 0.01). Trivial adverse events were reported. CONCLUSIONS: This meta-analysis of RCTs provides reliable evidence that BTA injection is superior to placebo or blank control group in improving scar quality and wound healing in the face and neck for Asians, and negative outcomes for BTA treatment in these patients include only trivial adverse events. However, inadequate evidence supports utilization of BTA in Caucasians for primary surgical scars or for scars in locations other than the face and neck. Further studies on the standardized injection regimen and technique of BTA are warranted for clinical practice.

来源:Aesthet Surg J,查看原文。版权归原作者所有。

引用

  1. Guo X, Song G, Zhang D, et al. Efficacy of Botulinum Toxin Type A in Improving Scar Quality and Wound Healing: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Aesthet Surg J. 2020. PMID: 31155638. doi:10.1093/asj/sjz165

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。